09:50 AM EST - TearLab Corporation : Announced that the commercial version of its next-generation in-vitro diagnostics testing platform, the TearLab Discovery™ System, is in conformity with all the applicable provisions of In Vitro Diagnostic Medical Devices Directive 98/79 EC enabling CE Marking of the device. CE Marking provides clearance in the European Union and European Free Trade Association member countries. TearLab Corporation
shares T.TLB are trading up $0.27 at $2.50.
